PMC8739978_01
Computed tomography (CT) scans revealed the changes of the primary lesion over time. (A) CT results (December 5, 2019) before first-line therapy (sintilimab combined with gemcitabine plus cisplatin). (B) CT results (February 14, 2020) at the first imaging evaluation. (C) CT results (May 13, 2020) at the end of the first-line systemic therapy. (D) CT results (April 19, 2021) at the latest imaging evaluation of the maintenance therapy.
fimmu-12-799822-g001.jpg
PMC8739978_01_fimmu-12-799822-g001.jpg
f1
Within the first 2 months of treatment, CT results showed that the tumor size was decreased from 83 mm x 72 mm to 64 mm x 64 mm ( Figures 1A, B  ). In May 2020, CT results showed that the huge tumor had shrunk to 22.5% of the size before treatment ( Figure 1C ). To date, there is no further enlargement of the primary tumor ( Figure 1D ).
Course of cancer antigen 19-9 (CA19-9) levels in relation to applied therapies: course of tumor markers over time. Arrows indicate application of first-line therapy (sintilimab combined with gemcitabine plus cisplatin) and maintenance therapy (sintilimab combined with capecitabine).
fimmu-12-799822-g002.jpg
PMC8739978_01_fimmu-12-799822-g002.jpg
f2
The CA19-9 level stayed below 10 U/mL ( Figure 2 ).